| DC11641 |
Cridanimod
Featured
|
A potent type I interferon (IFN) inducer that directly binds to STING and triggers a strong antiviral response through the TBK1/IRF3 route. |
|
| DC1022 |
ABT-737
Featured
|
ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM, respectively. |
|
| DC7363 |
AT-406
Featured
|
AT-406 (formerly known as SM-406) is an orally bioavailable potent IAP (inhibitor of apoptosis protein) of XIAP, cIAP1, and cIAP2 with Ki of 66.4 nM, 1.9 nM, and 5.1 nM, respectively. |
|
| DC3170 |
Cediranib
Featured
|
Cediranib (AZD2171) is a highly potent VEGFR2 inhibitor with IC50 of 0.5 nM, also inhibits Flt1/4 with IC50 of 5 nM/≤3 nM. |
|
| DC10657 |
COTI-2
Featured
|
COTI-2 is a small molecule candidate anti-cancer drug which can convert mutant p53 to wild-type conformation. |
|
| DC11642 |
Cridanimod sodium
Featured
|
Cridanimod sodium is a potent type I interferon (IFN) inducer that directly binds to STING and triggers a strong antiviral response through the TBK1/IRF3 route. |
|
| DC3156 |
Elesclomol (STA-4783)
Featured
|
Elesclomol (STA-4783) is a novel potent oxidative stress inducer that illicits pro-apoptosis events among tumor cells.. |
|
| DC7140 |
GSK1070916
Featured
|
GSK1070916 is a reversible and ATP-competitive inhibitor of Aurora B/C with IC50 of 3.5 nM/6.5 nM; displays >100-fold selectivity against the closely related Aurora A-TPX2 complex(IC50=490 nM). |
|
| DC8630 |
Ralimetinib 2MsOH(LY2228820)
Featured
|
LY2228820 is a novel and potent p38MAPK inhibitor (the IC50 for p38αMAPK and p38βMAPK were 7 nM and 3 nM, respectively). |
|
| DC7191 |
LY-2940680(Taladegib)
Featured
|
LY2940680 binds to the Smoothened (Smo) receptor and potently inhibits Hedgehog (Hh) signaling. |
|
| DC4179 |
Niraparib(MK4827) free base
Featured
|
MK-4827 is an inhibitor of poly (ADP-ribose) polymerase (PARP) with potential antineoplastic activity. |
|
| DC9862 |
Niraparib(MK4827) hydrochloride
Featured
|
MK-4827 is an inhibitor of poly (ADP-ribose) polymerase (PARP) with potential antineoplastic activity. |
|
| DC9576 |
Niraparib tosylate
Featured
|
MK-4827(Niraparib) tosylate is a selective inhibitor of PARP1/PARP2 with IC50 of 3.8 nM/2.1 nM; with great activity in cancer cells with mutant BRCA-1 and BRCA-2; >330-fold selective against PARP3, V-PARP and Tank1.
|
|
| DC4110 |
AZD-2281 (Olaparib)
Featured
|
Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1 and PARP2 with IC50 of 5 nM and 1 nM, respectively. |
|
| DC10054 |
Ombrabulin hydrochloride
Featured
|
Ombrabulin (AVE8062) hydrochloride is a synthetic derivative of CA-4-P, which inhibits growth in a large number of drug-resistant animal tumors and carcinogen-induced tumors. |
|
| DC11203 |
ORIC-101
Featured
|
ORIC-101 (ORIC101) is a highly potent, selective steroidal glucocorticoid receptor (GR) antagonist (IC50=5.6 nM) with reduced androgen receptor (AR) agonistic activity. |
|
| DC10070 |
PRIMA-1MET(APR-246)
Featured
|
PRIMA-1MET is methylated derivative of PRIMA-1. It can restore mutant p53 activity. |
|
| DC5151 |
Rucaparib phosphate (AG-14699, PF-01367338)
Featured
|
Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM with binding affinity to nine PARP domains. Phase 1/2. |
|
| DC8464 |
Rucaparib(AG-014447)
Featured
|
Rucaparib inactivates PARP activity in cells with homologous recombination DNA repair pathway mutations at LC50 values ranging from 1.3-5.5 μM. |
|
| DC7769 |
Tanomastat |
Tanomastat is an angiogenesis and Matrix Metalloproteinase inhibitor |
|
| DC10611 |
Trabectedin
Featured
|
Trabectedin (Ecteinascidin-743 or ET-743) is a novel antitumour agent of marine origin with potent antitumour activity both in vitro and in vivo. |
|
| DC7522 |
Triapine
Featured
|
Triapine is a potent ribonucleotide reductase inhibitor with broad spectrum antitumor activity by inhibiting DNA synthesis. Phase 2. |
|
| DC7607 |
Vatalanib
Featured
|
Vatalanib (PTK787) is an inhibitor of VEGFR2/KDR with IC50 of 37 nM, less potent against VEGFR1/Flt-1, 18-fold against VEGFR3/Flt-4. Phase 1/2. |
|
| DC8655 |
Vatalanib free base |
Vatalanib free base (PTK787 free base) is an inhibitor of VEGFR2/KDR with IC50 of 37 nM, less potent against VEGFR1/Flt-1, 18-fold against VEGFR3/Flt-4. |
|
